What is it about?
Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable and biocompatible hydrophobic drug carrier but lacks bone specificity. The poly-aspartic acid with 8 peptide sequences ((Asp)8) has a strong affinity to bone surface. Our novel design curcumin loaded (Asp)8-PEG-PCL nanoparticles showed strong anti-tumorigenic effect on MG63, MCF7 and HeLa cancer cells. In conclusion, (Asp)8-PEG-PCL nanoparticles were biocompatible, permeable in cells, potent carrier and efficient releaser of hydrophobic anticancer drug, and bone specific. The curcumin loaded (Asp)8-PEG-PCL nanoparticles showed strong anti-tumorigenic ability in vitro. Therefore, (Asp)8-PEG-PCL nanoparticles could be a potent carrier of hydrophobic anti-cancer drugs to treat the cancer metastasized to bone.
Featured Image
Why is it important?
Intravenously adminstrated (Asp)8-PEG-PCL nanoparticles were able to reach bone niche and showed strong bone affinity. (Asp)8-PEG-PCL nanoparticles were able to carry and release hydrophobic anticancer drugs with high efficiency. Therefore (Asp)8-PEG-PCL nanoparticles has strong potential to treat bone metastasised cancer.
Perspectives
This study is about basic research focused on bone metastasised cancer treatment strategy. Our novel design (Asp)8-PEG-PCL nanoparticles fulfil all chemical characteristics and biological properties as hydrophobic anticancer drug carrier targetting bone metastasised cancer. We believe that further in vivo and preclinical studies will lead this nanoparticles as an effective treatment model for cancer metastasised to bone.
Janak L Pathak
Tianjin University
Read the Original
This page is a summary of: Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone, International Journal of Nanomedicine, May 2017, Dove Medical Press,
DOI: 10.2147/ijn.s133787.
You can read the full text:
Contributors
The following have contributed to this page
